Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the first patient in the phase II idiopathic pulmonary fibrosis (IPF) study has been recruited in India.
AstraZeneca announced that its Calquence (acalabrutinib) has failed to meet the primary efficacy endpoint in the CALAVI phase II trials, which evaluated patients hospitalised with respiratory symptoms of Covid-19.
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of Covid-19 in high-risk outpatients and has begun enrolling patients.
Russia’s National Research Centre for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) announced that their Sputnik V vaccine has demonstrated a significant effect against Covid-19 patients in phase III clinical trials.
AstraZeneca and Amgen announced positive results from the NAVIGATOR Phase III trial for the potential new medicine tezepelumab in patients with severe, uncontrolled asthma
ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of the HIV Prevention Trials Network (HPTN) 084 study evaluating the safety and efficacy of investigational, long-acting, injectable cabotegravir for HIV prevention in women.
Pfizer and BioNTech announced that their mRNA-based vaccine candidate has shown a significant effect against Covid-19 patients in the first interim efficacy analysis of phase 3 clinical trial.
Novartis announced that its biologic medicine canakinumab has failed to achieve its primary endpoint in the phase III CAN-COVID trial.
TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter into a collaboration, development and licence agreement (CDLA).
GW Pharmaceuticals along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.